EP1244812A1 - Branched compound for use in nucleic acid detection and analysis reactions - Google Patents
Branched compound for use in nucleic acid detection and analysis reactionsInfo
- Publication number
- EP1244812A1 EP1244812A1 EP00985230A EP00985230A EP1244812A1 EP 1244812 A1 EP1244812 A1 EP 1244812A1 EP 00985230 A EP00985230 A EP 00985230A EP 00985230 A EP00985230 A EP 00985230A EP 1244812 A1 EP1244812 A1 EP 1244812A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- nucleic acid
- group
- moieties
- branched compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support
Definitions
- nucleic acid sequence often involves analysis of the nucleic acid sequence, structure or composition of a given organism or sample, frequently such analysis incorporates the step of, or requires nucleic acid amplification.
- One of the well known methods for nucleic acid amplification is the PCR, or polymerase chain reaction method also disclosed in US 4,683,195 and US 4,683,202.
- a nucleic acid sample serves as a template for a polymerase dependant in-vitro replication starting from for two separate primers.
- Polymerases are enzymes capable of synthesizing RNA or DNA making use of RNA or DNA as a template.
- RNA Ribonucleic acid
- amplification additionally requires an enzymatic reverse transcription into DNA (deoxyribonucleic acid), but equally often on DNA.
- PCR is becoming powerful tool in diagnostics. PCR kits are becoming available for the detection and analysis of various pathogenic organisms as well e.g. mutant alleles of human genes.
- PCR is mostly performed in-vitro, i.e. in a tube whereby the components are mostly supplied in liquid format.
- the components usually being, a polymerase, a buffer, a template, two or more oligonucleotides, may be bound to some form of a solid-phase.
- EP0787205 discloses the use of linker between the oligonucleotide and the solid-support.
- the primers on a solid-support are not freely available in the reaction. Thus primers remain a limiting factor.
- Such reactive groups have been e.g. amino groups. It is known in the art that such groups are very unstable, consequently when a given primer pair is arrayed on a support wherein the terminal group of the primers are e.g. amino groups it is to be expected, based on the instability of the groups, that after arraying the primers in each pair will not be present equimolar manner.
- the objects of the present invention were accomplished by providing for novel molecules with advantageous characteristics, processes for making these molecules, novel processes for in vitro nucleic acid synthesis for use with and without the novel molecules as well as kits containing molecules according to the invention for use in processes according to the invention.
- the object of the invention was accomplished by providing for a branched compound for use in nucleic acid detection and analysis reactions, comprising one linking moiety for attachment of the branched compound to a support at least one first branching moiety, and at least two nucleic acid moieties which are either directly or indirectly linked to the first branching moiety, whereby each of the nucleic acid moieties exhibits a free 3 ' -OH.
- the branched compound according to the invention preferentially has a first branching moiety that is formed by the linking moiety or a part thereof.
- nucleic acid moieties preferentially comprise a 5 'end and a free 3 ' -OH so that the at least two nucleic acid moieties are linked to a second branching moiety which in turn is linked to the first branching moiety.
- Li represents a linker moiety of variable length for attachment to a solid support, wherein Bi represents at least one branching moiety, Xi is one of at least two nucleic acid moieties, Yi represents the second of at least two nucleic acid moieties and the nucleic acid moieties may be extended by a polymerase.
- a solid-support may be any support used to perform solid phase reactions, solid phase reactions and solid-support reactions are used with equal meaning and shall be understood as such reactions in which one or more compounds is attached to a solid matter of any given shape or chemical structure.
- a solid-phase reaction is a reaction in which at least one compound may not move freely through diffusion in the reaction.
- the inventors observe a large enhancement in reaction efficiency when applying the compound according to the invention to e.g. in-vitro nucleic acid detection and analysis reactions.
- the inventors attribute this unexpected behaviour to the fact that two or more two nucleic acid moieties are in close spatial proximity.
- the molecule according to the invention thus solves one of the problems in the prior art namely the availability of oligonucleotides for extension.
- the reaction product of e.g. X ⁇ may, in a subsequent cycle of a number of cycles of an in an in-vitro nucleic acid synthesis reaction, serve as a template for a reaction with Yi and since these are in close molecular vicinity, this reaction will run very efficiently.
- the variable linker moiety Li makes it possible to overcome the drawbacks of known solid-phase reactions where the nucleic acids were in close vicinity to the solid-phase and thus cross-react with it to remain refrained from taking part in the actual reaction.
- the compound according to the invention thus combines for the very first time a number of characteristics in itself which the inventors have found to be important for success in e.g. in-vitro nucleic acid detection and analysis reactions, (i)
- the compound according to the invention provides for the possibility to define the distance from a given solid-support. This is accomplished through the linker moiety Li which also serves to couple the compound to the solid-support, (ii)
- the compound according to the invention provides for the possibility to bring in close vicinity two or more nucleic acids (e.g. Xi and Yi) involved in one reaction, thus solving the problem of a lack of diffusion of e.g.
- nucleic acids in in-vitro nucleic acid synthesis reactions (iii)
- the compound according to the invention provides for nucleic acids Xi and Yi which are not sterically hindered as the branching moiety Bi permits them to become available in the reaction.
- Figure 9B shall illustrate schematically some of the advantageous the branched compound according to the invention provides for.
- an efficient in-vitro nucleic acid synthesis reaction is dependant on either one of two events occurring, (i) a template molecule, whereby this stems from the sample with which the reaction was started, to reach a primer Xi, through diffusion or, (ii) a reaction product from a previous extension e.g. from Xi to be in spatial vicinity and thus serve as a template for an extension by Yi (See also Fig. 9A and 9B).
- a branching molecule is defined as a molecule capable of binding 2 or more nucleic acids as well as a linker L ⁇ .
- nucleic acid molecules For a better understanding we shall define the components of nucleic acid molecules as follows:
- Deoxyribonucleic acid and ribonucleic acid are thread-like macromolecules, DNA comprising a chain of deoxyribnucleotides, and RNA comprising a chain of ribonucleotides.
- a "nucleotide” consists of a nucleoside and one or more phosphate groups; a “nucleoside” consists of a nitrogenous base linked to a pentose sugar.
- the phosphate group is attached to the fifth carbon (“5") hydroxyl group (“OH”) of the pentose sugar; however, it can also be attached to the third-carbon hydroxy group (“3'-OH").
- the pentose sugar is deoxy-ribose
- the pentose-sugar is ribose.
- the DNA bases are adenine ("A"), cytosine ("C”), guanine ("G”), and thymine (“T”). These base are the same for RNA except that uracil (“U”) replaces thymine in natural RNA, i.e. RNA isolated from a living organism.
- deoxynucleosides are as follows: deoxyadeno- sine ("dA”), deoxycytosine (“dC”), deoxyguanosine (“dG”), and deoxythymidine (“dT”).
- abbreviations A, C, G and T shall refer to the DNA as well as RNA bases unless specified otherwise.
- nucleic acid moieties Xi and Yi may be selected from the group comprising de- oxynucleotides, dideoxynucleotides, ribonucleotides or modified nucleotides as specified above. If the term nucleotides is used, any of the above may be meant unless specified otherwise.
- the inventors have found that it may, in some cases be advantageous to extend the distance between the branching molecule B and the oligonucleotides or oligonucleotide analogues by additionally adding one or more spacers to the molecule according to the invention.
- the molecule additionally comprises spacers SPi and SP 2 with which the molecular distance between the free 3' OH ends of oligonucleotides or oligonucleotide analogues and the branch Bi may be defined.
- a possible structure is shown below in formula 2.
- the branched compound additionally comprises two or more spacers SPi and SP 2 according to the following formula 2:
- Li represents a linker moiety of variable length for attachment to a solid support
- Bi represents at least one branching moiety
- Xi is one of at least two nucleic acid moieties
- Yi represent the second of at least two nucleic acid moieties
- the nucleic acid moieties may be extended by a polymerase
- SPi and SP 2 respectively represent spacer moieties which serve to define the distance between the branch moiety Bi and the nucleic acid moieties Xi and Yi.
- spacers are optional and one may envision molecules where only one of the two oligonucleotides or oligonucleotide analogues are separated by a spacer from the branching molecule
- this is one of the essential features of the present invention as the variation of spacer length allows for adjustment to different template lengths and types.
- spacers SPi and SP 2 are polymeric units comprising monomers. Although they may be chosen from the group comprising nucleotides, nucleotide analogues, abasic deoxyribose moieties, abasic ribose moieties, carbon chains which in turn may aliphatic or aromatic or even poly- glycoles, they are not limited to these.
- oligonucleotides or oligonucleotide analogue may be used as a spacer as long as they fulfil the functional requirement of defining a distance between the branch and the free 3'-OH and do not hinder the polymerase from extending oligonucleotides or oligonucleotide analogue.
- the inventors have empirically found that a suitable distance between the 3'-OH group and the branch molecule lies between 3 and 350 angstrom, preferably between 30 and 120 angstrom. These values were established by testing different spacer types and calculating the resulting lengths from the molecule type.
- SPi and SP 2 are polymeric units comprising monomers chosen from the group comprising nucleotides, nucleotide analogues, abasic deoxyribose moieties, abasic ribose moieties, carbon chains.
- the SPi and SP 2 are polymeric units comprising monomers of nucleotides or nucleotide analogues.
- nucleotides are to be understood as stretches of the same nucleotide or any given mixture of different nucleotides. The inventors have found between one and a hundred, more preferably between 10 and 30 to be suited, according to the distances described in more detail below.
- a suitable distance between the 3'-OH group and the branch molecule lies between 3 and 350 angstrom, preferably between 30 and 120 angstrom. These values were established by testing different spacer types and calculating the resulting lengths from the molecule type.
- the branched compound further comprising a reactive group (Ri) as represented by formula 3.
- L] represents a linker moiety of variable length for attachment to a solid support, wherein Bi represents at least one branching moiety, wherein Xj is one of at least two nucleic moieties, wherein Yi represent the second of at least two nucleic acid moieties, wherein the nucleic acid moieties may be extended by a Polymerase, wherein SPi and SP 2 respectively represent spacer moieties which serve to define the distance between the branch moiety Bi and the nucleic acid moieties Xi and Yi.
- Such a reactive group Ri may be selected from a group comprising amino group, hydroxyl group, carboxyl group, aldehyde group, thiol group, organo-silane group and phosphate group.
- the linker moiety (Li) of variable length consists of polymeric units selected from the group comprising, nucleotides, nucleotide analogues, abasic deoxyribose moieties, abasic ribose moie- ties, carbon chains between about 3 carbons and 22 carbons, preferably between 3 carbons and 18 carbons in length, such chains may be aliphatic or aromatic, and polyglycoles.
- linker moiety of variable length as long as they fulfil the functional requirement of defining a distance between the solid- support and the branch moiety.
- the inventors have empirically found that a suitable distance between the branch moiety and the solid-support lies between 3 and 350 angstrom, preferably between 30 and 120 angstrom. These values were established by testing different linker moieties and calculating the resulting lengths from the molecule type.
- the linker moiety (Li) of variable length consists of polymeric units comprising monomers of nucleotides or nucleotide analogues.
- nucleotides are to be understood as stretches of the same nucleotide or any given mixture of different nucleotides. The inventors have found between one and a hundred, more preferably between 10 and 30 to be suited, according to the distances described in more detail above.
- nucleic acid moieties As described above, two or more nucleic acid moieties (Xi, Yi, Zi, etc.) are coupled to the branch moiety B ⁇ . It is an essential feature of the invention that at least to of these nucleic acid moieties carry a free 3' hydroxyl group and may thus be extended by a polymerase.
- Xi and Y ⁇ consist of between 2 and 100 nucleotides in a more preferred embodiment of the invention between 10 and 30 nucleotides.
- oligonucleotide moiety will be used when the nucleic acid moieties consist of between 2 and 100 nucleotides.
- oligonucleotide moieties Xi and Yi have the same sequence it is preferred if consist of different nucleotide sequences.
- the oligonucleotide moiety is characterised in that Xj and Yi stem from the sense and anti-sense strand of a nucleic acid molecule. That means, if the were to anneal to a mixture of e.g. DNA, they would anneal to the plus and the minus strand respectively of a given DNA double helix.
- the oligonucleotide moieties thus point towards each other with their free 3'-OH groups.
- their positioning upon hybridisation to a DNA double helix is so, that, a stretch of target DNA is located between the two positions of the respective oligonucleotide moieties X and Y.
- the oligonucleotide moieties may (i) have the same sequence, (ii) have different sequences, (iii) have different sequences that hybridise to different targets, (iv) have different sequences that hybridise to the same target at different locations on the target, (v) have different sequences that hybridise to the plus and minus strand of one DNA double helix and many so on.
- the oligonucleotide moieties may (i) have the same sequence, (ii) have different sequences, (iii) have different sequences that hybridise to different targets, (iv) have different sequences that hybridise to the same target at different locations on the target, (v) have different sequences that hybridise to the plus and minus strand of one DNA double helix and many so on.
- the reactive group R ⁇ serves to couple the branched compound to a solid- support.
- the reactive group is an organo-silane group.
- Formula four below depicts the entire molecule according to this preferred embodiment.
- Ri, R 2 , and R 3 are identical or different alkoxy groups and "branched compound” refers to the entire compound according to the invention excluding the reactive group RI and n is an integer from 0 to 18.
- This novel compound has surprisingly shown unexpected results when compared to similar molecules previously used in solid-phase enzymatic reactions with respect to but not limited to the following effects, its adsorption capacity to a solid-support, it's availability in enzymatic reactions, thus its contribution to the efficiency of e.g. solid-phase nucleic acid synthesis reactions.
- the alkoxy groups Ri, R 2 , and R 3 may, e.g. by methoxy, ethoxy or the like.
- organo-silane moieties comprising mixtures of different alkoxy groups.
- R] may be a methoxy, R 2 an ethoxy and R 3 a methoxy.
- R may be a methoxy, R 2 an ethoxy and R 3 a methoxy.
- (Ri) is a propyltrimeth- oxysilyl group according to the following formula 5,
- the branched compound according to the invention is attached to a solid-phase.
- the branched compound is connected to a support via the linking moiety Li of which the reactive group R ⁇ has undergone a reaction with a group on the surface of the solid-support to form a covalent or non-covalent bond.
- Such solid-phase may be chosen from the group comprising nitrocellulose, nylon, controlled- pore glass beads (CPG), polystyrene, activated dextran, modified polystyrene, styrene-acrylnitril- copolymers, polycarbonate, cellulose, polyamide and glass.
- CPG controlled- pore glass beads
- the solid-phase is glass.
- Such glass may be a glass slide, as used e.g. for microscopy, glass vessels or containers, glass fibres, glass beads or other Si comprising glass entities.
- the compound according to the invention may be spotted onto, pipetted onto, sprayed onto or otherwise brought onto such a glass support.
- Possible methods are, application by means of a needle, capillary, dispenser and piezo pipette is preferable, e.g. an apparatus similar to the kind known for ink jet printers.
- the compound according to the invention may be used in various ways some of which shall be mentioned here.
- the compound is particularly suited and may thus be used in preferred embodiments of the invention for nucleic acid synthesis reactions, primer extension reactions, reverse transcription reactions of RNA into DNA or nucleic acid hybridisation experiments (see also Figures 1 to 3).
- the compound is used in in-vitro nucleic acid synthesis reactions and hybridisation experiments.
- the compound may be bound to a solid support such as glass.
- the compound represents one or more nucleic acid probes to which a target, i.e. the sample is bound.
- nucleic acid hybridisation or synthesis reactions for identifying the sequence of a nucleic acid.
- the branched compound may be used in nucleic acid hybridisation or synthesis reactions for analysing the expression pattern of genes.
- oligonucleotides or nucleic acid fragments e.g. PCR products represent the nucleic acid moieties according to the invention which are attached via the rest of the branched compound to a suited solid-support to form an array of various probes, labelled RNA or pre-amplified RNA is hybridised to the array and the positive hybridisations scored as expressed genes.
- oligonucleotides or nucleic acid fragments e.g. PCR products represent the nucleic acid moieties according to the invention which are attached via the rest of the branched compound to a suited solid-support to form an array of various probes, labelled RNA or pre-amplified RNA is hybridised to the array and the positive hybridisations scored as expressed genes.
- the compound according to the invention may be used to distinguish single base mismatches.
- the general principle of such an approach is disclosed in U.S. Pat. 5,700,638 where, such experiments are described in Example 2.
- US Pat. 5,552,270 also describes such an approach.
- the compound according to the invention comprises an oligonucleotide of defined sequence.
- An array is generated comprising numerous different sequences each suited to test a defined sequence.
- the branched compound according to the invention may be used to map genomes of organisms.
- oligonucleotides or nucleic acid fragments e.g. PCR products represent the nucleic acid moieties according to the invention which are attached via the rest of the branched compound to a suited solid-support to form an array of various probes, labelled genomic fragments are sequentially hybridised in numerous steps in such a way that the relationship between individual fragments becomes apparent.
- the invention shall also cover a process for a nucleic acid synthesis reaction of one or more selected regions of one or more target nucleic acids comprising the steps of a) combining the sample containing the target region with at least on nucleotide triphosphate, a thermally stable polymerase, a buffer and at least one branched compound according to the invention, b) exposing the reaction mixture to at least one temperature cycle including at least a high temperature denatura- tion phase and a lower temperature extension phase, and thereby producing at least a partially amplified product.
- At least one branched compound according to the invention is bound to a solid-support.
- the branched compound according to the invention comprises preferably between 3 and 100 nucleotides more preferably between 10 and 50 nucleotide most preferably between 12 and 25 nucleotides for each nucleic acid moiety. It is essential in this context that the nucleic acid moiety is of sufficient length to bind the desired target nucleic acid molecule with sufficient stringency.
- PNA-DNA hybrid oligonucleotides see Finn, P. J. et al., N.A.R. 24, 3357-3363 (1996), Koch, T. et al., Tetrahedron Letters 36, 6933- 6936 (1995), Stetsenko, D. A.
- a DNA polymerase may be selected from the group comprising Taq DNA polymerase, Tth DNA polymerase or Klentaq (Taq DNA polymerase (-exo5'-3')- Korolev et al., (1995) Proc. Natl. Acad. Sci. USA 92, 9246-9268.
- Taq DNA polymerase (-exo5'-3')- Korolev et al., (1995) Proc. Natl. Acad. Sci. USA 92, 9246-9268.
- the use of Taq DNA polymerase in the method of the present invention is especially preferred.
- numerous different thermally stable polymerases may be used.
- a DNA polymerase which has a decreased discrimination against the four ddNTPs with respect to wild-type Taq DNA polymerase in the buffer or under the conditions used for thermal cycling is preferred. More preferably, a DNA polymerase Taq polymerase carrying a "Tabor-Richardson" mutation or a functional derivative thereof which also lacks 5 '-3' exonuclease activity such as, for example, AmplitaqFSTM (Taq DNA polymerase (-exo5'-3')(F667Y), Tabor and Richardson (1995), loc.
- TaquenaseTM Taq DNA polymerase ⁇ 235(-exo5'-3')(F667Y), Tabor and Richardson (1995), loc. cit.
- Thermo- SequenaseTM Taq DNA polymerase (-exo5'-3')(F667Y), Tabor and Richardson (1995), loc. cit.) as well as mixtures thereof or other DNA polymerases and mixtures thereof which are thermally stable can be used in the process of the present invention.
- Thermo SequenaseTM or any other DNA polymerase having a high ability to incorperate ddNTPs in the method of the present invention is especially preferred.
- a DNA polymerase which has a decreased discrimination against labelled nucleotides may be used.
- the present invention i.e. the process also provides for the use of two or more polymerases in the process or additional enzymes such as amplification enhancing reagents such as thermally stable pyrophosphatase or enzymes which enhance the processivity of the polymerase such as PCNA (proliferating cell nuclear antigen) homologues. Enzyme mixtures may be equally applied.
- the number of thermal cycles may range from about 1 to about 50 depending on the amount of template DNA and its purity. Generally, the inventors have found that very surprisingly extremely short cycles give good results. As the availability of the compound according to the invention is high in the process according to the invention the cycle period may be short, thus disadvantageous denaturing of proteins, e.g. the polymerase when in contact with glass occurs at a lower rate and the reaction may run efficiently without loss of function of enzyme.
- cycling consists of (i) a denaturing cycle, (ii) an annealing cycle and (iii) an extension cycle. Alternatively, only two cycles may be applied, (i) a denaturing cycle and (ii) an annealing and extension cycle.
- the denaturing cycle is performed at between 100°C and 85°C, more preferably at between 98°C and 90°C, most preferably at between 96°C and 92°C.
- the annealing cycle is performed at between 80°C and 45°C, more preferably at between 70°C and 50°C, most preferably at between 60°C and 55°C.
- the extension cycle is performed at between 80°C and 50°C, more preferably at between 75°C and 60°C, most preferably at between 73°C and 68°C.
- the denaturing cycle is performed for 3 minutes, more preferably for 30 seconds, most preferably for under 10 seconds.
- the annealing cycle is performed for 3 minutes, more preferably for 30 seconds, most preferably for under 10 seconds.
- the extension cycle is performed for 3 minutes, more preferably for 30 seconds, most preferably for under 10 seconds, however the extension time vary depending on the length of the template, in particular the extension time may be raised if the template length increases.
- Buffers components which can be used can include, but are not limited to, Tris-HCl at a pH of about 7.0 to 10 and concentration of about 2 to 60 mM, ammonium sulfate at a concentration of about 10-20 mM, preferably 15 mM, MgCl2 at a concentration of about 1 to 10 mM, and optionally, about 0.05 mM mercaptoethanol, about 0.28% Tween® 20 and/or about 0.02% Nonidet® 40.
- Nucleotide triphosphates are preferably deoxynucleotides and can be selected from, but are not limited to, dGTP, dATP, dTTP and dCTP.
- derivatives of deoxynucleotides which are defined as those deoxynucleotides which are capable of being incorperated by a thermally stable DNA polymerase into nascent DNA molecules synthesized in the thermal cycling reaction, can also be used according to the invention.
- Such derivatives include, but are not limited to thionucleotides, 7-deaza-2'-dGTP, 7-deaza-2'-dATP as well as deoxyinosine triphosphate which may also be used as a replacement deoxynucleotide for dATP, dGTP, dTTP or dCTP.
- deoxynucleotides and derivatives thereof are preferably used at a concentration of about 50 ⁇ M to about 4 mM.
- the nucleotides are mixes of all four nucleotides A, C, G, and T and at 200 ⁇ M each.
- single and differential labels may consist of the group comprising enzymes such as ⁇ - galactosidase, alkaline phosphatase and peroxidase, enzyme substrates, coenzymes, dyes, chro- mophores, fluorescent, chemiluminescent and bioluminescent labels such as FITC, Cy5, Cy5.5, Cy7, Texas-Red and IRD40(Chen et al. (1993), J. Chromatog. A 652: 355-360 and Kambara et al. (1992), Electrophoresis 13: 542-546), ligands or haptens such as biotin, and radioactive isotopes such as 3 H, 35 S, 32 P 125 I and 14 C.
- enzymes such as ⁇ - galactosidase, alkaline phosphatase and peroxidase
- enzyme substrates such as enzymes such as ⁇ - galactosidase, alkaline phosphatase and peroxidase,
- the nucleic acid molecule to be amplified can be present in the form of total genomic DNA, which is preferably in an uncloned or unpurified form.
- the genomic DNA has a length greater than or equal to 2 kb.
- all forms of template may be used, e.g. purified nucleic acids, i.e. nucleic acids where one fraction may be enriched or not, one example being plasmid DNA the other purified genomic DNA.
- the process may be suited for use with complex mixtures of DNA such being purified but not substantially fractionated genomic DNA or non-complex mixtures such being purified and substantially fractionated DNA e.g. plasmid DNA.
- the nucleic acid molecule to be amplified can be present in the form of RNA.
- One polymerase or a mixture of two polymerases maybe utilised: a first DNA polymerase for example, Taq polymerase, and a second DNA polymerase with the capability to reverse transcribe RNA into DNA preferably Taq DNA polymerase (Jones et al., Nucl. Acids Res. 17: 8387-8388 (1989)) or Tth DNA polymerase (Myers et al., Biochemistry 30: 7666-7672 (1991)).
- the invention also covers a kit for use in molecular biology or chemistry comprising at least the compound according to the invention.
- the kit may also comprise other reagents or enzymes such as buffers, nucleotides or the like.
- DNA Oligonucleotides were synthesised using standard cyanoethyl posphoramidite chemistry on an ABI 392 DNA/RNA Synthesizer (Caruthers MH, Barone AD, Beaucage SL, Dodds DR, Fisher EF, McBride LJ, Matteucci M, Stabinsky Z, Tang JY Chemical synthesis of deoxyoligo- nucleotides by the phosphoramidite method, Methods Enzymol 154, 287-313 (1987)). Primary amino groups with an hexyl carbon atom spacer were introduced using the N-MMT-C6- aminomodifier (Cruachem Cat. No. 22-8401-17).
- Oligonucleotides were synthesized using the trityl-on mode and purified via HPLC (BioCad, PE Biosystems) using Oligo R3 reversed phase chromatography media (PE Biosystems Cat. No. 1-1339-06) and an on-column detritylation standard protocol.
- the oligonucleotides contained specific 20 or 19 nucleotides together with a T 9 or T 15 spacer and were designed for the amplification of a 223 bp fragment of the polylinker sequence of pBlueScript KS + (Stratagene Cat. No. 212207).
- the single branched amplification molecule was synthesised using cyanoethyl posphoramidite chemistry on an ABI 392 DNA/RNA Synthesizer.
- the 3' terminal amino group was introduced by starting synthesis with an aminolinker column (Cruachem Cat. No. 19-7850-80).
- the 5'- branch was introduced using either symmetric or assymmetric branching CE phosphoramidites (Cruachem Cat. No. 22-8424-17 or 22-8425-17).
- Reactive carboxyl groups at the 5'-ends were introduced using Carboxy-dT CE phosphoramidite (Glen Research Cat.No. 10-1035-02), while primary amino groups were introduced using the N-MMT-C6-aminomodifier (Cruachem Cat.
- the carboxymodified branch (2 nmol) was incubated with the aminomodified oligonucleotides in molar excess.
- the reaction was accomplished by incubation of the carboxy and amino components in 100 ⁇ l aqueous solution containing 9 mg of the peptide condensing agent l-ethyl-3-(3- dimethylaminopropyl)-carbodiimide (EDC) 6 hours at 4 °C.
- arrays After spotting slides were incubated for 4 hours in a humid chamber to allow rehydration of the DNA, washed once in 0.2% SDS, twice in water, and incubated for 5 minutes in 0.25 % sodium borohydride in phosphate buffered saline for blocking free ami- noreactive groups of the glass slide. Arrays are then submerged in water 2 minutes at 95 °C, transferred to 0.2%) SDS for 1 minute and rinsed twice in water. After drying, arrays can be stored in the dark at ambient temperature.
- Amplification reactions were performed in a 25 ⁇ l volume containing 50 mM Tris-HCl at pH 8.5, 30 mM KC1, 3 mM magnesium chloride, 12.5 ⁇ g bovine serum albumine, 200 ⁇ M each dGTP, dATP and dTTP, 100 ⁇ M dCTP, 4 ⁇ M Cy5-dCTP (Amersham Pharmacia Biotech, Cat. No. PA 55021), 0.1 unit Taq DNA Polymerase and 3 frnole of template DNA (pBlueScript KS + plasmid DNA).
- the reaction chamber was formed by sealing the reaction droplet on the slide with FrameSeal Slide Chambers (Biozym Diagnostik, Cat. No. 621741).
- the silde is then attached to a modified frame (originally designed for holding glass capillaries) which fits to the reaction chamber of the thermal-cycler device (Idaho Technology, Thermo-Cycler 1605). Reactions are cycled with the following profile one initial cycle at 94°C for 30 seconds, thirty cycles for 10 seconds at 94 °C, for 15 seconds at 60°C, for 25 seconds at 74 °C and one final cycle for 30 seconds at 74°C.
- Oligonucleotides were synthesised using standard cyanoethyl posphoramidite chemistry on an ABI 392 DNA/RNA Synthesizer. Primary amino groups with an hexyl carbon atom spacer were introduced using the N-MMT-C6-aminomodifier (Cruachem Cat. No. 22-8401-17). Oligonucleotides were synthesized using the trityl-on mode and purified via HPLC (BioCad, PE Biosystems) using Oligo R3 reversed phase chromatography media (PE Biosystems Cat. No. 1-1339- 06) and an on-column detritylation standard protocol.
- the purified oligonucleotide or single branched amplification molecule containing the 5' hex- ylamino modification (100 pmoles) was incubated in 100 ⁇ l of a 100 mM 1 ,4-phenylene diiso- thiocyanate (DITC) containing solution of pyrridine : dimethylformamide (ratio 1 : 9) for 2 hours at ambient temperature
- DITC 100 mM 1 ,4-phenylene diiso- thiocyanate
- ratio 1 : 9 dimethylformamide
- branched oligonucleotides were synthesized using an automated DNA synthesizer and reagents commercially available from Glen Research (Virginia, USA) following the manufacturer's recommendations for dilution, coupling conditions and deprotection.
- the Fmoc protecting group of the branch was removed under basic conditions (e.g. with 20% piperidine in DMF) in order to start synthesis of the second specific DNA oligonucleotide primer. 6) The second specific oligonucleotide was synthesised, also in 5' -> 3' direction.
- the Y-shaped oligonucleotide contained three 3'-ends, of which two were the functional 3'-hydroxyl groups of the two different DNA primers and one contained an C7-amino modification for coupling to the silane moiety according to the invention.
- Fig. 1 shows a schematic representation of a solid-phase in-vitro nucleic acid synthesis reaction.
- the figure shows a oligonucleotide wherein, the oligonucleotide as an arrow and an organo- silane moiety as zig-zag line, both coupled via the organo-silane moiety to a solid support (G).
- G a solid support
- an in-vitro nucleic acid synthesis reaction is schematically shown.
- a target molecule (H) anneals to the oligonucleotide (B) where it is used as a template and oligonucleotide is extended by a polymerase.
- the extended oligonucleotide may serve as a template for a further oligonucleotide (C) which must be in sufficiently close vicinity.
- the oligonucleotide (C) now uses the template (D) and is extended to the full-length product (E).
- efficient synthesis relies on equimolarity and close vicinity of two or more different oligonucleotide required in one reaction.
- Fig. 2 shows a schematic representation of a solid-phase in-vitro nucleic acid synthesis reaction.
- the figure shows a branched compound according to the invention wherein, the branched compound comprises two free 3'-OH groups and an organo-silane moiety as zig-zag line, both coupled via the organo-silane moiety to a solid support (G).
- G a solid support
- an in-vitro nucleic acid synthesis reaction is schematically shown.
- a target molecule (H) anneals to the nucleic acid moiety of the branched compound (B) where it is used as a template and the nucleic acid moiety is extended by a polymerase.
- nucleic acid moiety may serve as a template for a further nucleic acid moiety (C) which is by definition in sufficiently close vicinity.
- the nucleic acid moiety (C) now uses the template (D) and is extended to the full-length product (E).
- Fig. 3
- Fig. 3 shows a schematic representation of a solid-phase in-vitro nucleic acid synthesis reaction starting from mRNA including the step of prior reverse transcription coupled to an amplification step.
- the figure shows a branched compound according to the invention wherein, the branched compound comprises two free 3'-OH groups and an organo-silane moiety as zig-zag line, both coupled via the organo-silane moiety to a solid support (G).
- G solid support
- a to F an in-vitro nucleic acid reverse transcription with coupled amplification reaction is schematically shown.
- a target mRNA molecule (H) anneals to the nucleic acid moiety (B) where it is used as a template and the nucleic acid moiety is extended by a polymerase with reverse transcriptase activity. Thereafter, the extended nucleic acid moiety may serve as a template for a further nucleic acid moiety (C) which is by definition in sufficiently close vicinity.
- the nucleic acid moiety (C) now uses the template (D) and is extend to the full-length product (E).
- efficient synthesis relies on equimolarity and close vicinity of two or more different nucleic acid moiety required in one reaction.
- the compound according to the invention takes place in reverse transcription as well as subsequent amplification.
- Fig. 4 shows a comparison between binding amino-modified oligonucleotides to silane-treated glass (panels A, B) and binding oligonucleotides carrying a terminal silane group to normal glass (panels C, D).
- the compound according to the invention carries such a organo-silane group as shown here in combination with a standard oligonucleotide.
- the reactive group R ⁇ is an organo-silane group and thus the compound according to the invention will spot as in this example.
- the 3' P- labeled oligonucleotides (10.000 cpm) were spotted onto the respective glass slides and scanned (panels A, C).
- the branched compound according to the invention carries such a organo-silane group as shown here in combination with a standard oligonucleotide.
- the reactive group Ri is an organo-silane group and thus the compound according to the invention will spot as in this example.
- Fig. 5 shows an experiment for the determination of the binding capacity of an organo-silane modified oligonucleotide to normal untreated glass.
- Fig. 7 shows schematically the reactions leading to the derivatization of an oligonucleotide with an organo-silane moiety according to a preferred embodiment of the invention.
- An oligonucleotide containing a 5' hexylamino modification is first reacted with 1 ,4-phenylene diisothiocyanate (reaction A) and further reacted with 1, 3-aminopropyltrimethoxy-silane (reaction B).
- reaction B 1, 3-aminopropyltrimethoxy-silane
- the compound bearing the glass-reactive silane group can then be attached to e.g. glass supports (reaction C).
- Fig. 7 shows a preferred embodiment of the compound according to the invention.
- the nucleic acid moieties were attached separately.
- Fig. 8 shows a preferred embodiment of the compound according to the invention.
- the nucleic acid moieties were attached separately using two identical bifunctional groups.
- Fig. 9 A shows a prior-art nucleic acid synthesis on solid-phase (E) .
- template (A) is supplied through diffusion only.
- the oligonucleotides of sense (C) and antisense (D) are not in sufficient vicinity or are sterically hindered (not shown here) they may not serve as template upon elongation.
- the oligonucleotide (B) is elongated factors such as concentration, steric hindrance etc. will decide whether it may serve as a template in a subsequent cycle.
- Fig. 9 B shows a nucleic acid synthesis process on solid-phase (G) according to the invention.
- diffusion template (H) reaches any of the nucleic acid moieties, the may serve themselves as a template (C and D) or neighbouring branched compounds (E and F) may serve as templates.
- the process according to the invention overcomes fundamental problems connected to the prior-art.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00985230A EP1244812A1 (en) | 1999-12-21 | 2000-12-21 | Branched compound for use in nucleic acid detection and analysis reactions |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99125485A EP1110967A1 (en) | 1999-12-21 | 1999-12-21 | Compound comprising a biomolecule moiety and an organo-silane moiety |
EP99125484A EP1111068A1 (en) | 1999-12-21 | 1999-12-21 | Branched compound for use in nucleic acid detection and analysis reactions |
EP99125484 | 1999-12-21 | ||
EP99125485 | 1999-12-21 | ||
US21121700P | 2000-06-13 | 2000-06-13 | |
US21120900P | 2000-06-13 | 2000-06-13 | |
US211217P | 2000-06-13 | ||
US211209P | 2000-06-13 | ||
PCT/EP2000/013098 WO2001046464A1 (en) | 1999-12-21 | 2000-12-21 | Branched compound for use in nucleic acid detection and analysis reactions |
EP00985230A EP1244812A1 (en) | 1999-12-21 | 2000-12-21 | Branched compound for use in nucleic acid detection and analysis reactions |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1244812A1 true EP1244812A1 (en) | 2002-10-02 |
Family
ID=56290094
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00985230A Withdrawn EP1244812A1 (en) | 1999-12-21 | 2000-12-21 | Branched compound for use in nucleic acid detection and analysis reactions |
EP00991249A Withdrawn EP1250344A2 (en) | 1999-12-21 | 2000-12-21 | Compound comprising a nucleic acid moiety and an organo-silane moiety |
EP00993511A Withdrawn EP1252172A2 (en) | 1999-12-21 | 2000-12-21 | Compound comprising a peptide moiety and an organo-silane moiety |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00991249A Withdrawn EP1250344A2 (en) | 1999-12-21 | 2000-12-21 | Compound comprising a nucleic acid moiety and an organo-silane moiety |
EP00993511A Withdrawn EP1252172A2 (en) | 1999-12-21 | 2000-12-21 | Compound comprising a peptide moiety and an organo-silane moiety |
Country Status (3)
Country | Link |
---|---|
EP (3) | EP1244812A1 (en) |
AU (3) | AU3163101A (en) |
WO (3) | WO2001046464A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005108625A2 (en) * | 2001-07-13 | 2005-11-17 | Nanosphere, Inc. | Method for preparing substrates having immobilized molecules and substrates |
EP1509336B1 (en) | 2002-05-20 | 2011-01-19 | Danisco US Inc. | Synthesis of inorganic structures using templation and catalysis by self assembled repeat protein polymers |
DE60334718D1 (en) | 2002-05-20 | 2010-12-09 | Danisco Us Inc | PEPTIDE DERIVATIVES AND THEIR USE TO SYNTHESIS V |
US7534621B2 (en) | 2003-02-07 | 2009-05-19 | Canon Kabuhsiki Kashia | Method of producing probe medium and method of immobilizing probe using probe medium |
US20050142094A1 (en) | 2003-03-12 | 2005-06-30 | Manoj Kumar | Use of repeat sequence protein polymers in personal care compositions |
US7297678B2 (en) | 2003-03-12 | 2007-11-20 | Genencor International, Inc. | Use of repeat sequence protein polymers in personal care compositions |
US7456147B2 (en) | 2003-05-14 | 2008-11-25 | Dow Corning, Corporation | Controlled release of active agents utilizing repeat sequence protein polymers |
MXPA05012201A (en) | 2003-05-14 | 2006-02-10 | Dow Corning | Repeat sequence protein polymer active agent conjugates, methods and uses. |
US20050208538A1 (en) | 2003-12-29 | 2005-09-22 | Nurith Kurn | Methods for analysis of nucleic acid methylation status and methods for fragmentation, labeling and immobilization of nucleic acids |
US7940746B2 (en) | 2004-08-24 | 2011-05-10 | Comcast Cable Holdings, Llc | Method and system for locating a voice over internet protocol (VoIP) device connected to a network |
US9206418B2 (en) | 2011-10-19 | 2015-12-08 | Nugen Technologies, Inc. | Compositions and methods for directional nucleic acid amplification and sequencing |
WO2013072408A1 (en) * | 2011-11-15 | 2013-05-23 | Swetree Technologies Ab | Surface-functionalized cellulosic fibres, method of manufacture thereof and uses thereof |
SG11201404243WA (en) | 2012-01-26 | 2014-08-28 | Nugen Technologies Inc | Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation |
CA2877094A1 (en) | 2012-06-18 | 2013-12-27 | Nugen Technologies, Inc. | Compositions and methods for negative selection of non-desired nucleic acid sequences |
US20150011396A1 (en) | 2012-07-09 | 2015-01-08 | Benjamin G. Schroeder | Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing |
US9822408B2 (en) | 2013-03-15 | 2017-11-21 | Nugen Technologies, Inc. | Sequential sequencing |
CN105849264B (en) | 2013-11-13 | 2019-09-27 | 纽亘技术公司 | For identifying the composition and method that repeat sequencing reading |
WO2015131107A1 (en) | 2014-02-28 | 2015-09-03 | Nugen Technologies, Inc. | Reduced representation bisulfite sequencing with diversity adaptors |
EP3177740B1 (en) | 2014-08-06 | 2021-01-13 | Nugen Technologies, Inc. | Digital measurements from targeted sequencing |
US11099202B2 (en) | 2017-10-20 | 2021-08-24 | Tecan Genomics, Inc. | Reagent delivery system |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS608745B2 (en) * | 1978-02-14 | 1985-03-05 | 三洋化成工業株式会社 | Immunologically active substance-frosted glass composite, method for producing the same, and measurement reagent containing the composite |
US4284553A (en) * | 1980-06-20 | 1981-08-18 | North Carolina State University At Raleigh | Reversible method for covalent immobilization of biochemicals |
IL78678A0 (en) * | 1986-05-04 | 1986-08-31 | Yeda Res & Dev | Substituted silica |
US5359100A (en) * | 1987-10-15 | 1994-10-25 | Chiron Corporation | Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers |
GB9104453D0 (en) * | 1991-03-02 | 1991-04-17 | Tepnel Medical Ltd | Improvements relating to enzymes |
US5290440A (en) * | 1992-06-23 | 1994-03-01 | Research Corporation Technologies, Inc. | High performance chiral selector |
US5641658A (en) * | 1994-08-03 | 1997-06-24 | Mosaic Technologies, Inc. | Method for performing amplification of nucleic acid with two primers bound to a single solid support |
FR2726286B1 (en) * | 1994-10-28 | 1997-01-17 | Genset Sa | SOLID PHASE NUCLEIC ACID AMPLIFICATION PROCESS AND REAGENT KIT USEFUL FOR CARRYING OUT SAID PROCESS |
AU5871196A (en) * | 1995-05-23 | 1996-12-24 | Hybridon, Inc. | Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced |
US5912332A (en) * | 1996-07-26 | 1999-06-15 | Hybridon, Inc. | Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides |
US5916750A (en) * | 1997-01-08 | 1999-06-29 | Biogenex Laboratories | Multifunctional linking reagents for synthesis of branched oligomers |
DE69808661T3 (en) * | 1997-07-28 | 2012-05-03 | Gen-Probe Inc. | SEQUENCE ANALYSIS OF NUCLEIC ACIDS |
WO1999011820A1 (en) * | 1997-09-02 | 1999-03-11 | Isis Pharmaceuticals, Inc. | Compositions and methods for the identification and quantitation of deletion sequence oligonucleotides in synthetic oligonucleotide preparations |
US6537749B2 (en) * | 1998-04-03 | 2003-03-25 | Phylos, Inc. | Addressable protein arrays |
US6048695A (en) * | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
DE19825899A1 (en) * | 1998-06-10 | 1999-12-16 | Memorec Medical Molecular Rese | Immobilized oligo- or polynucleotide product useful for identifying and quantifying polynucleotides |
-
2000
- 2000-12-21 AU AU31631/01A patent/AU3163101A/en not_active Abandoned
- 2000-12-21 WO PCT/EP2000/013098 patent/WO2001046464A1/en not_active Application Discontinuation
- 2000-12-21 AU AU28432/01A patent/AU2843201A/en not_active Abandoned
- 2000-12-21 EP EP00985230A patent/EP1244812A1/en not_active Withdrawn
- 2000-12-21 AU AU21709/01A patent/AU2170901A/en not_active Abandoned
- 2000-12-21 WO PCT/EP2000/013100 patent/WO2001046214A2/en active Search and Examination
- 2000-12-21 EP EP00991249A patent/EP1250344A2/en not_active Withdrawn
- 2000-12-21 EP EP00993511A patent/EP1252172A2/en not_active Withdrawn
- 2000-12-21 WO PCT/EP2000/013099 patent/WO2001046213A2/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO0146464A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP1252172A2 (en) | 2002-10-30 |
EP1250344A2 (en) | 2002-10-23 |
AU2170901A (en) | 2001-07-03 |
WO2001046214A3 (en) | 2001-12-27 |
AU2843201A (en) | 2001-07-03 |
WO2001046213A3 (en) | 2002-05-10 |
WO2001046213A2 (en) | 2001-06-28 |
WO2001046214A2 (en) | 2001-06-28 |
AU3163101A (en) | 2001-07-03 |
WO2001046464A1 (en) | 2001-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001046464A1 (en) | Branched compound for use in nucleic acid detection and analysis reactions | |
AU770217B2 (en) | Ligation assembly and detection of polynucleotides on solid-support | |
US7074569B2 (en) | Mobility-modified nucleobase polymers and methods of using same | |
US5118802A (en) | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside | |
US5015733A (en) | Nucleosides possessing blocked aliphatic amino groups | |
KR100274519B1 (en) | Improved method for nucleic acid amplification | |
US5118800A (en) | Oligonucleotides possessing a primary amino group in the terminal nucleotide | |
US6590093B1 (en) | Orthoester protecting groups | |
EP0742287B1 (en) | Modified nucleic acid probes | |
JP4791043B2 (en) | Methods and compositions for synthesizing two or more oligonucleotides in tandem on the same solid support | |
CA1244786A (en) | Synthesis of amino-derivitized oligonucleotides | |
JPH07505529A (en) | Probe compositions and methods | |
JPH08508473A (en) | Novel derivatives useful for nucleic acid sequencing | |
JPH08322600A (en) | Application of dna polymerase with 3'-peculiar calibration activity | |
US20040072202A1 (en) | Modified nucleic acid probes | |
WO1995008556A1 (en) | Reagents comprising chimeric molecules of nucleic acids and nucleic acid analogs | |
WO2005021786A1 (en) | A method of sequencing nucleic acids by ligation of labelled oligonucleotides | |
EP1111068A1 (en) | Branched compound for use in nucleic acid detection and analysis reactions | |
EP1110967A1 (en) | Compound comprising a biomolecule moiety and an organo-silane moiety | |
US20020031776A1 (en) | Enzymatic labeling and detection of DNA hybridization probes | |
JP2000512843A (en) | Method of forming a hybrid complex whose stability is only slightly dependent on the base composition of the two hybridized nucleic acid molecules | |
JP5128031B2 (en) | Method for producing nucleic acid introduced with label using RecA protein | |
BASES et al. | THYMINE DIMERS-DNA LESIONS INDUCED BY SUNLIGHT CIS-SYN THYMINE DIMER PHOSPHORAMIDITE NOW AVAILABLE | |
AU2002303356A1 (en) | Mobility-modified nucleobase polymers and methods of using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020718 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: VBC-GENOMICS BIOSCIENCE RESEARCH GMBH |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HILLER, REINHARD Inventor name: MUELLER, MANFRED Inventor name: HUBER, MARTIN Inventor name: SCHMIDT, WOLFGANG |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060404 |